RAPT Therapeutics (RAPT) Operating Leases (2022 - 2024)
Historic Operating Leases for Therapeutics (RAPT) over the last 3 years, with Q3 2024 value amounting to $2.6 million.
- Therapeutics' Operating Leases fell 4879.73% to $2.6 million in Q3 2024 from the same period last year, while for Sep 2024 it was $2.6 million, marking a year-over-year decrease of 4879.73%. This contributed to the annual value of $4.5 million for FY2023, which is 3462.38% down from last year.
- Per Therapeutics' latest filing, its Operating Leases stood at $2.6 million for Q3 2024, which was down 4879.73% from $3.2 million recorded in Q2 2024.
- Therapeutics' Operating Leases' 5-year high stood at $7.1 million during Q1 2022, with a 5-year trough of $2.6 million in Q3 2024.
- For the 3-year period, Therapeutics' Operating Leases averaged around $5.3 million, with its median value being $5.7 million (2023).
- Per our database at Business Quant, Therapeutics' Operating Leases tumbled by 1214.85% in 2023 and then crashed by 4879.73% in 2024.
- Over the past 3 years, Therapeutics' Operating Leases (Quarter) stood at $6.8 million in 2022, then crashed by 34.62% to $4.5 million in 2023, then plummeted by 41.75% to $2.6 million in 2024.
- Its last three reported values are $2.6 million in Q3 2024, $3.2 million for Q2 2024, and $3.8 million during Q1 2024.